The prognostic value and potential subtypes of immune activity scores in three major urological cancers

Immune‐based rather than cancer‐based classification systems are becoming an important additional component for prognostic prediction. Herein, we investigate the status of tumor–immune interaction and prognostic value of immune activity scores in bladder urothelial carcinoma (BLCA), kidney renal cle...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2021-04, Vol.236 (4), p.2620-2630
Main Authors: Shi, Bowen, Qi, Jun
Format: Article
Language:English
Subjects:
Adenocarcinoma
Bladder
Bladder cancer
Cancer
CD4 antigen
CD8 antigen
Classification systems
Dendritic cells
Genomes
immune activity scores
Lymphocytes
Lymphocytes T
Macrophages
Medical prognosis
Natural killer cells
Principal components analysis
Prognosis
Prostate
Recruitment
Regression analysis
Renal cell carcinoma
subtype
TCGA
TIP
Tumors
urological cancer
Urothelial carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune‐based rather than cancer‐based classification systems are becoming an important additional component for prognostic prediction. Herein, we investigate the status of tumor–immune interaction and prognostic value of immune activity scores in bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), and prostate adenocarcinoma (PRAD) from The Cancer Genome Atlas dataset and tracking the tumor immunophenotype platform. Traditional clinicopathological parameters still are effective predictors for prognosis. Comparison of 23‐set, seven‐step immune activity scores, and its distribution between favorable and adverse outcome groups within each cancer type and among cancer types show that each cancer has a distinct tumor–immune pattern. Adjusted overall immune activity scores based on the binary logistic regression analysis show a great discrimination ability in the progression‐free survival (p = .0056 in BLCA, p 
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.30018